Cost comparison between mycophenolate mofetil and cyclophosphamide- azathioprine in the treatment of lupus nephritis

Journal of Rheumatology

Volumn 36, Issue 1, 2009, Pages 76-81

  Tse, Kai Chung ^a   Tang, Colin S O ^a   Lam, Man Fai ^a   Yap, Desmond Y H ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Azathioprine; Cyclophosphamide; Infection; Lupus nephritis; Mycophenolate mofetil

Indexed keywords

ACICLOVIR; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; CEFTAZIDIME; CEFUROXIME; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; LEVOFLOXACIN; MEROPENEM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; SERUM ALBUMIN; SULPERAZON;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CREATININE CLEARANCE; DEMOGRAPHY; DISEASE SEVERITY; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DRUG COSTS; FEMALE; HOSPITAL COSTS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PNEUMONIA; YOUNG ADULT;

EID: 58149517586     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080517     Document Type: Article

References (12)

1. Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-62.
2. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
3. Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002;115:705-9.
4. Cross J, Dwomoa A, Andrews P, et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005;100:c92-100.
5. Chan TM, Tse KC, Tang CS, Mok MY, Li FK, Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
6. Tse KC, Tang CS, Lio WI, Lam MF, Chan TM. Quality of life comparison between corticosteroid and mycophenolate mofetil and corticosteroid and oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 2006;15:371-9.
7. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
8. Wilson EC, Javne DR, Dellow E, Fordham RJ. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology Oxford 2007;46:1096-101.
9. HM Treasury. The green book. Appraisal and evaluation in central government. Annex 7: discount rate. London: HM Treasury; 2003.
10. Kirkwood BR, Sterne JA. Essential medical statistics. Oxford: Blackwell Publishing; 2003.
11. Chan TM. Mycophenolate mofetil in the treatment of lupus nephritis - 7 years on. Lupus 2008;17:617-21.
12. Sullivan SD, Garrison LP Jr, Best JH. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group. J Am Soc Nephrol 1997;8:1592-8.